Aicardi-Goutieres syndrome-like encephalitis in mutant mice with constitutively active MDA5
Aicardi-Goutieres syndrome-like encephalitis in mutant mice with constitutively active MDA5
复制标题
具有组成型活性 MDA5 的突变小鼠中的 Aicardi-Goutieres 综合征样脑炎
DOI:
10.1093/intimm/dxaa073
复制
发表时间:
2020
影响因子:
4.4
通讯作者:
Fujita Takashi
中科院分区:
文献类型:
--
作者:
Onizawa Hideo;Kato Hiroki;Kimura Hiroyuki;Kudo Tomoo;Soda Nobumasa;Shimizu Shota;Funabiki Masahide;Yagi Yusuke;Nakamoto Yuji;Priller Josef;Nishikomori Ryuta;Heike Toshio;Yan Nan;Tsujimura Tohru;Mimori Tsuneyo;Fujita Takashi
MDA5 is a cytoplasmic sensor of viral RNA, triggering type I interferon (IFN-I) production. Constitutively active MDA5 has been linked to autoimmune diseases such as systemic lupus erythematosus, Singleton–Merten syndrome (SMS) and Aicardi–Goutières syndrome (AGS), a genetically determined inflammatory encephalopathy. However, AGS research is challenging due to the lack of animal models. We previously reported lupus-like nephritis and SMS-like bone abnormalities in adult mice with constitutively active MDA5 (Ifih1G821S/+), and herein demonstrate that these mice also exhibit high lethality and spontaneous encephalitis with high IFN-I production during the early postnatal period. Increases in the number of microglia were observed in MDA5/MAVS signaling- and IFN-I-dependent manners. Furthermore, microglia showed an activated state with an increased phagocytic capability and reduced expression of neurotrophic factors. Although multiple auto-antibodies including lupus-related ones were detected in the sera of the mice as well as AGS patients,Ifih1G821S/+Rag2−/−mice also exhibited up-regulation of IFN-I, astrogliosis and microgliosis, indicating that auto-antibodies or lymphocytes are not required for the development of the encephalitis. The IFN-I signature without lymphocytic infiltration observed inIfih1G821S/+mice is a typical feature of AGS. Collectively, our results suggest that theIfih1G821S/+mice are a model recapitulating AGS and that microglia are a potential target for AGS therapy.